TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $55.00

TG Therapeutics (NASDAQ:TGTX) had its price target raised by analysts at HC Wainwright from $49.00 to $55.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 121.06% from the company’s current price.

Other analysts have also issued research reports about the company. B. Riley boosted their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. TD Cowen began coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, The Goldman Sachs Group upped their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, TG Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $37.67.

TG Therapeutics Trading Up 2.1 %

TGTX traded up $0.52 during trading hours on Tuesday, reaching $24.88. The company’s stock had a trading volume of 1,560,444 shares, compared to its average volume of 3,637,472. TG Therapeutics has a fifty-two week low of $9.81 and a fifty-two week high of $26.99. The stock has a market cap of $3.85 billion, a PE ratio of 40.79 and a beta of 2.19. The business’s 50-day moving average is $23.51 and its 200-day moving average is $20.17. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The firm’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.73 EPS. As a group, equities research analysts predict that TG Therapeutics will post 0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TG Therapeutics

Several large investors have recently bought and sold shares of TGTX. NBC Securities Inc. boosted its stake in TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in TG Therapeutics in the second quarter valued at $35,000. Blue Trust Inc. boosted its stake in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 849 shares in the last quarter. ORG Wealth Partners LLC acquired a new position in TG Therapeutics in the third quarter valued at $53,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in TG Therapeutics in the first quarter valued at $58,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.